Purdue Pharma L.P.

Type: Company
Name: Purdue Pharma L.P. (Purdue Pharma L.P)
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Global Infection Prevention and Control Market : 2014-2018

Press ReleaseTechNavio Announces the Publication of its Research Report - Global Infection Prevention and Control Market 2014-2018TechNavio recognizes the following companies as the key players in the Global Infection Prevention and Control Market: Belimed ... [Published MarketResearch.com - 11 hours ago]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

FDA Approves Purdue Pharma L.P.???s Hard-to-Abuse Narcotic Painkiller

FDA Approves Purdue Pharma’s Hard-to-Abuse Narcotic PainkillerJuly 28, 2014By Renee Morad , BioSpace.com Breaking News StaffThe Food and Drug Administration approved a drug combining oxycodone and naloxone that is designed to discourage abuse by those ... [Published BioSpace - Jul 28 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Harder-to-abuse oxycodone painkiller approved

FDA has approved a new oxycodone painkiller that’s designed to be more difficult for drug abusers to exploit.Targiniq ER (Purdue Pharma) is an extended-release tablet that combines oxycodone, the active ingredient in OxyContin, with the drug naloxone. ... [Published Drugtopics.com - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Studies Examining the Relationship between the Chemical Structure of Protoxin II and Its Activity on Voltage Gated Sodium Channels

Discovery Research, Purdue Pharma L.P., 6 Cedar Brook Drive, Cranbury, New Jersey 08512, United States ... [Published Journal of Medicinal Chemistry - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 5 reports

FDA approves Targiniq ER from Purdue Pharma

SILVER SPRING, Md. — The Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets). The drug is an extended-release, long-acting opioid analgesic that treats pain severe enough to require ... [Published Drug Store News - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Combo Pain-Killer Designed to Be Tougher to Abuse

(Newser)–The FDA has approved a new form of OxyContin that unites two unlikely bedfellows in an attempt to curb abuse, reports AP . The drug from Purdue Pharma is called Targiniq ER, and it combines oxycodone—the main pain-killing ingredient in OxyContin, ... [Published Newser - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

GSK, J&J push for genetic engineering of opium

A Tasmanian poppy field--Courtesy of Periptus, Creative Commons (CC-BY SA 3.0)A battle over genetic engineering is going on within the pharmaceutical industry. Makers of opioids want a larger, more certain supply of raw materials, most of which originate ... [Published FiercePharmaManufacturing - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

FDA Prioritises Review of ‘Abuse-Deterrent’ Painkiller

Purdue Pharma LP's hydrocodone bitartrate tablet (HYD) is undergoing "priority review" by the Food and Drug Administration (FDA), the company recently announced.Reports said the tablet, if approved, will be the first painkiller with an "abuse-deterrent ... [Published International Business Times Australia - Jul 22 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 4 reports

Purdue cleared to market additional strength of Butrans patch

STAMFORD, Conn. – Purdue Pharma has received approval from the Food and Drug Administration for a new 7.5 mcg/hour dosage strength of the Butrans Transdermal System CIII, an opioid pain medication patch.Purdue said Wednesday that five strengths of Butrans ... [Published Chain Drug Review - Jul 17 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 2 reports

Priority Review for Purdue’s anti-abuse hydrocodone

The US FDA has granted Priority Review Designation to Purdue Pharma’s hydrocodone bitartrate tablet which has abuse-deterrent technology.Priority Review is given by the FDA to drugs that could make major improvements to treatment of serious conditions, ... [Published In-Pharmatechnologist - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 3 reports

KBR To Construct Oral Solid Dosage Production Facility For Purdue Pharma Manufacturing L.P. In Durham, N.C.

KBR (NYSE: KBR) announced today that KBR Building Group, a subsidiary within KBR's Services Group, has been awarded a contract by Purdue Pharma Manufacturing L.P. to build a new Oral Solid Dosage manufacturing plant in Durham, N.C. The 188,000-square-foot, ... [Published EPC Engineer - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 3 reports

FDA grants Priority Review designation for Purdue’s hydrocodone bitartrate

Privately held US drugmaker Purdue Pharma has been granted Priority Review designation by the US Food and Drug Administration for its once-daily, single-entity hydrocodone bitartrate tablet.This has been formulated with abuse-deterrent properties that ... [Published Pharma Letter - Jul 09 2014]

Quotes

"The FDA is committed to combatting the misuse and abuse of all opioids, and the development of opioids that are harder to abuse is needed in order to help address the publicpublic health crisis of prescription drugdrug abuse in the U S ,” said Sharon Hertz, M D , deputy director of the division of anesthesia, analgesia and addiction products in the FDA’s Center for Drug Evaluation and Research."
"Well done to the manufacturer for placing some built-in pharmacological protections," an ER physician tells CNN . "It won't stop orally ingested overdose deaths, but will limit some of its street marketability." But another doctor, the president of Physicians for Responsible Opioid Prescribing, sees a risk if doctors perceive this drug as "safe" and over-prescribe...
"If we really want to turn this epidemic around, the most important thing is to stop creating new cases of addiction" he told the Times. "Coming up with new gimmicks isn't going to help."
"The FDA is committed to combatting the misuse and abuse of all opioids, and the development of opioids that are harder to abuse is needed in order to help address the publicpublic health crisis of prescription drugdrug abuse in the U S ,” Dr. Sharon Hertz, deputy director of the Division of Anesthesia, Analgesia, and Addiction Products at the FDA, said in a statement . “Encouraging the development of opioids with abuse-deterrent properties is just one component of a broader approach to reducing abuse and misuse, and will better enable the FDA to balance addressing this problem with meeting the needs of the millions of people in this country suffering from pain.”"

More Content

All (134) | News (104) | Reports (0) | Blogs (28) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Global Infection Prevention and Control Market ... [Published MarketResearch.com - 11 hours ago]
FDA Approves Purdue Pharma L.P.???s Hard-to-Abu... [Published BioSpace - Jul 28 2014]
FDA Accredits New Combination Painkillers Desig... [Published MedIndia - Jul 26 2014]
Harder-to-abuse oxycodone painkiller approved [Published Drugtopics.com - Jul 25 2014]
FDA approves Purdue’s abuse-deterrent opioid Ta... [Published Pharma Letter - Jul 25 2014]
FDA approves pain drug that has reduced risk of... [Published PMLive - Jul 25 2014]
Studies Examining the Relationship between the... [Published Journal of Medicinal Chemistry - Jul 25 2014]
FDA approves a new painkiller [Published Medical Marketing And Media - Jul 24 2014]
Even a Light Rain Can Send Raw Sewage Into New ... [Published Fair Warning - Jul 24 2014]
Combo Pain-Killer Designed to Be Tougher to Abuse [Published Newser - Jul 24 2014]
Extended-Release Oxycodone With Abuse-Deterrent... [Published P&T Community - Jul 24 2014]
FDA approves Targiniq ER from Purdue Pharma [Published Drug Store News - Jul 24 2014]
Purdue earns a nod--and a quick slap--for abuse... [Published FierceBiotech - Jul 24 2014]
Extended-Release Opioid Receives FDA Approval, ... [Published Medical Daily - Jul 24 2014]
Ten Top Litigators to Lead ACIs Drug and Medica... [Published PRWeb - Jul 24 2014]
FDA approves new opioid pain reliever designed ... [Published DailyMe.Com - Jul 24 2014]
In brief: FDA approves painkiller designed to t... [Published Spokesman-Review.com - Jul 24 2014]
Top New York Prosecutor Sheds Light on What Mil... [Published Express Milwaukee - Jul 24 2014]
FDA approves ER oxycodone formulation designed ... [Published Orthopedics Today - Jul 24 2014]
FDA Approves Abuse-Deterrent Oxycodone/Naloxone... [Published American Journal of Public Health - Jul 24 2014]
FDA approves new painkiller from Purdue Pharma ... [Published FOXBusiness.com - Jul 23 2014]
FDA approves extended-release oxycodone with ab... [Published FOX6Now.com - Jul 23 2014]
Not yet a class action: the Nova Scotia Supreme... [Published Lexology - Jul 23 2014]
12th Cold Chain GDP & Temperature Management Lo... [Published Global Logistics & Supply Chain Strategies - Jul 22 2014]
Monday Moves—July 21, 2014 [Published Medical Marketing And Media - Jul 22 2014]
Jay-Z and Scarface: pharma staff’s anonymous Wi... [Published In-Pharmatechnologist - Jul 22 2014]
GSK, J&J push for genetic engineering of opium [Published FiercePharmaManufacturing - Jul 22 2014]
FDA Prioritises Review of ‘Abuse-Deterrent’ Pai... [Published International Business Times Australia - Jul 22 2014]
Will new Politico poll encourage more Democrats... [Published Washington Examiner - Jul 21 2014]
Alcohol Excipients Market Research, Trends and ... [Published MyNewsDesk - Jul 21 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Purdue Pharma gets FDA approval for 7.5 mcg/hou... [Published PBR - News - Jul 21 2014]
Purdue Pharma has announced that the US Food & Drug Administration (FDA) has approved a new 7.5 mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII. Five strengths of Butrans will now be available: 5 mcg/hour, 7.5 mcg/hour, 10 ...
Purdue Pharma L.P. Receives FDA Approval for 7.... [Published PR Newswire: Policy & Public Interest - Jul 16 2014]
STAMFORD, Conn., July 16, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) approved a new 7.5 mcg/hour dosage strength of Butrans® (buprenorphine) Transdermal System CIII. Five strengths of Butrans will ...
FDA Grants Priority Review Designation for Purd... [Published PR Newswire: Policy & Public Interest - Jul 08 2014]
STAMFORD, Conn., July 8, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet (HYD).  This ...
Prescription Opioid Makers Are Big Donors to An... [Published Firedoglake - Jul 08 2014]
On average, opioid prescription rates are noticeably lower in medical marijuana states.  Coincidence? A fascinating article highlights many of the conflicts of interest at the heart of top anti-marijuana legalization groups  in the country : The ...
MS CONTIN (Morphine Sulfate) Tablet, Film Coate... [Published DailyMed Drug Label Updates for the last seven ... - Jun 22 2014]
Updated Date: Jun 19, 2014 EST ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Purdue Pharma L.P., a Leading Pharmaceutical Co... [Published Financial Services - Jun 18 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.